The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $2.77 in the prior trading day, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $2.72, down -1.81%. In other words, the price has decreased by -$1.81 from its previous closing price. On the day, 1.16 million shares were traded. ACRS stock price reached its highest trading level at $2.9 during the session, while it also had its lowest trading level at $2.71.
Ratios:
Our goal is to gain a better understanding of ACRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.03 and its Current Ratio is at 7.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 19, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $2 to $7.
Jefferies Upgraded its Hold to Buy on November 19, 2024, whereas the target price for the stock was revised from $2 to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Leonard Braden Michael bought 206,025 shares of ACRS for $256,357 on Aug 05 ’24. The 10% Owner now owns 14,250,000 shares after completing the transaction at $1.24 per share. On Aug 02 ’24, another insider, Leonard Braden Michael, who serves as the 10% Owner of the company, bought 167,544 shares for $1.29 each. As a result, the insider paid 216,400 and bolstered with 14,043,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 194292032 and an Enterprise Value of 68815160. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.05 while its Price-to-Book (P/B) ratio in mrq is 1.49. Its current Enterprise Value per Revenue stands at 2.541 whereas that against EBITDA is -1.106.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 1.89%, while the 200-Day Moving Average is calculated to be 73.51%.
Shares Statistics:
The stock has traded on average 2.33M shares per day over the past 3-months and 986060 shares per day over the last 10 days, according to various share statistics. A total of 71.42M shares are outstanding, with a floating share count of 59.91M. Insiders hold about 16.13% of the company’s shares, while institutions hold 75.64% stake in the company. Shares short for ACRS as of 1732838400 were 2480701 with a Short Ratio of 1.07, compared to 1730332800 on 2409457. Therefore, it implies a Short% of Shares Outstanding of 2480701 and a Short% of Float of 4.14.
